Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer assumed coverage on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report report published on Wednesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $16.00 price target on the biopharmaceutical company’s stock.

ABEO has been the subject of a number of other research reports. StockNews.com downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Up 3.7 %

ABEO opened at $5.26 on Wednesday. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $9.01. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The company has a market capitalization of $228.66 million, a P/E ratio of -1.96 and a beta of 1.79. The stock has a fifty day moving average of $5.58 and a 200-day moving average of $5.85.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Twinbeech Capital LP acquired a new position in Abeona Therapeutics in the fourth quarter valued at about $58,000. Squarepoint Ops LLC bought a new position in Abeona Therapeutics in the fourth quarter valued at about $67,000. Jane Street Group LLC bought a new position in Abeona Therapeutics in the third quarter valued at about $84,000. Oxford Asset Management LLP bought a new position in Abeona Therapeutics in the fourth quarter valued at about $118,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Abeona Therapeutics in the third quarter valued at about $151,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.